Zealand Pharma A/S American Depositary Shares
ZEAL
ZEAL was delisted on the 29th of September, 2022.
11 hedge funds and large institutions have $10.4M invested in Zealand Pharma A/S American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
10% more funds holding
Funds holding: 10 → 11 (+1)
17% less capital invested
Capital invested by funds: $12.5M → $10.4M (-$2.1M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$6.43M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.66K |
| 3 |
Jane Street
New York
|
+$3.36K |
| 4 |
Morgan Stanley
New York
|
+$2.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.75M |
| 2 |
AIC
AWM Investment Company
New York
|
-$73.7K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$10.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7K |
ZEAL Hedge Fund Activity: Q2 2022 in Review
11 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Zealand Pharma A/S American Depositary Shares (ZEAL) for Q2 2022, worth a combined $10.4M — down 17% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ZEAL positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $6.43M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $7.75M sold.
- 11 institutional investors held Zealand Pharma A/S American Depositary Shares (ZEAL) as of Q2 2022, up from 10 in Q1 2022.
- Funds reported $10.4M of Zealand Pharma A/S American Depositary Shares stock for Q2 2022, down 17% quarter-over-quarter.
- 2 funds opened new Zealand Pharma A/S American Depositary Shares positions in Q2 2022 and 1 closed out, a net change of +1 holder.
- The largest Zealand Pharma A/S American Depositary Shares buyer in Q2 2022 was Goldman Sachs, an estimated $6.43M added.
- The largest Zealand Pharma A/S American Depositary Shares seller in Q2 2022 was Farallon Capital Management, an estimated $7.75M sold.
Based on aggregated 13F filings for Q2 2022.